Get Free Access to Session Slides

How Best to Treat cN1 Prostate Cancer - Karim Fizazi

Karim Fizazi summarizes how best to treat node-positive (cN+) prostate cancer patients at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi, yet he notes, none have been published in the setting of node-positive prostate cancer. In this presentation Dr. Fizazi discussed the role of abiraterone in high-risk non-metastatic prostate cancer patients shown in the STAMPEDE trial, whether there is a difference between node positive disease in the pelvis compared to the retroperitoneum, and he concluded his presentation by emphasizing that there is currently insufficient evidence to support any specific treatment in node-positive prostate cancer. 


Karim Fizazi, MD, Ph.D., is a medical oncologist, Head of the Department of Cancer Medicine at the Institute Gustave Roussy (IGR), Villejuif, France and a Professor in Oncology at the University of Paris.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.